Immunogenicity and Safety Study of a Hexavalent DTaP-IPV-Hep B-PRP-T Combined Vaccine or Infanrix hexa™ Concomitantly Administered With 13-Valent Pneumococcal Conjugate Vaccine (PCV13), at 3, 5, 11 to 12 Months of Age in Healthy Infants in Europe To demonstrate the non-inferiority of the Hexaxim vaccine to the licensed Infanrix hexa vaccine, both co-administered with Prevenar 13, in terms of seroprotection or vaccine response rates to all anti...

• Country None
• organs None
• Specialty None

Immunogenicity and Safety of the Inactivated, Split-Virion Influenza Vaccine, Northern Hemisphere 2008-2009 Formulation (Intramuscular Route) To evaluate the compliance, in terms of immunogenicity, of the inactivated, split-virion influenza vaccine Northern Hemisphere 2008-2009 formulation with the requirements of the Committee for Human M...

• Country None
• organs None
• Specialty None

Immunogenicity and Safety of the Influenza Vaccine (Split Virion, Inactivated), Northern Hemisphere 2009-2010 Formulation (Intradermal Route) In subjects aged 18 to 59 years for the ID influenza vaccine 9 µg and in subjects aged 60 years or older for the ID influenza vaccine 15 µg: 1) To evaluate compliance, in terms of immunogenicity, of...

• Country None
• organs None
• Specialty None

Study of Sanofi Pasteur's dengue vaccine in Subjects Aged 2 to 45 Years in the Philippines Safety and reactogenicity Viremia Dengue immune responses and Persistence of antibodies

• Country None
• organs None
• Specialty None

Immunogenicity and Safety of the Influenza Vaccine (Split Virion, Inactivated), Northern Hemisphere 2010-2011 Formulation (Intradermal Route) In each group: 1) To evaluate compliance, in terms of immunogenicity, of the corresponding strength of the ID influenza vaccine NH 2010-2011 formulation with the requirements of the Committee for Prop...

• Country None
• organs None
• Specialty None

Safety and Immunogenicity of an Intramuscular H5N1 Inactivated, Split Virion Influenza Vaccine Adjuvanted with AF03 in Adults and Elderly subjects • To describe the safety profile of the vaccines (injection site reactions and systemic events) either 21 days after each injection in subjects vaccinated following the D0-D21 or D0-D42 schedules or, ...

• Country None
• organs None
• Specialty None

Immunogenicity of the Purified Vero Rabies Vaccine – Serum Free in Comparison with the Reference Purified Vero Rabies Vaccine in Pre-exposure Use in Healthy Adults To demonstrate that VRVg (PR1) is at least as immunogenic as the reference vaccine, Verorab (PR2), in terms of seroconversion rate at D42, i.e. 14 days after the last vaccination of primary vaccinatio...

• Country None
• organs None
• Specialty None

Immunogenicity and Safety of the Inactivated, Split-Virion Influenza Vaccine, Northern Hemisphere 2006-2007 Formulation (Intramuscular Route) To check the compliance, in terms of immunogenicity, of the inactivated, split-virion influenza vaccine Northern Hemisphere 2006-2007 formulation with the requirements of the European Medicines Agency...

• Country None
• organs None
• Specialty None

Immunogenicity and Safety of the Inactivated, Split-Virion Influenza Vaccine, Northern Hemisphere 2007-2008 Formulation (Intramuscular Route) To check the compliance, in terms of immunogenicity, of the inactivated, split-virion influenza vaccine Northern Hemisphere 2007-2008 formulation with the requirements of the Committee for Human Medic...

• Country None
• organs None
• Specialty None

Immunogenicity and Safety Study of a Hexavalent DTaP-IPV-HB-Hib Combined Vaccine in a 3-dose Primary Series in Healthy Infants in Europe Estudio de inmunogenicidad y de seguridad de una vacuna combinada hexavalente DTaP-IPV-HB-Hib en una serie primaria de 3 dosis en lactantes sanos en Europa Groups 1 and 2 only To demonstrate the non-inferiority of the DTaP-IPV-HB-Hib vaccine to the control Infanrix hexa vaccine, both co-administered with Prevenar 13, in terms of seroprotection or vaccine...

• Country None
• organs None
• Specialty None